Hugh Montgomery, MD

University College London, United Kingdom

Disclosure(s): AstraZeneca: Advisor/Consultant; Millfield Medical Ltd: Advisor/Consultant; UK National Institute for Health Research's Comprehensive Biomedical Research Centre at University College London Hospitals: Grant/Research Support

Poster(s):

• 1160 - Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1918 - Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1924 - Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET